Journal: Frontiers in Physiology

Article Title: Kaempferol ameliorates gestational diabetes mellitus by regulating STAT3-associated AIM2 inflammasome activation and ferroptotic injury in trophoblasts

doi: 10.3389/fphys.2026.1857741

Figure Lengend Snippet: STAT3-associated changes in STAT1/IRF1 signaling and AIM2 expression in HG-stimulated trophoblast cells. (A, B) RT-qPCR was performed to assess STAT3 knockdown efficiency and AIM2 mRNA expression changes in HTR-8/SVneo cells subjected to different treatments. (C–F) Western blot analysis was performed to evaluate the expression levels of p-STAT1, STAT1, IRF1, and AIM2 proteins under different experimental conditions. N = 3, not significant, ** P <0.01, *** P <0.001.

Article Snippet: Following blocking, the membranes were incubated overnight at 4°C with primary antibodies, including AIM2 (1:1000, catalog number ab93015, Abcam), Glutathione Peroxidase 4 (GPX4, 1:1000, 52455, Cell Signaling Technology, CST), solute carrier family 7 member 11 (SLC7A11, 1:1000, 23276, CST), phospho-STAT3 (p-STAT3, 1:1000, 9145, CST), STAT3 (1:1000, 12640, CST), pro-IL-1β (1:1000, 12703, CST), IL-1β (1:1000, ab283818, Abcam), cleaved caspase-1 (1:1000, 4199, CST), pro-caspase-1 (1:1000, 24232, CST), STAT1 (1:1000, 9172T, CST), phospho-STAT1 (p-STAT1, 1:1000, 9177S, CST), IRF1 (1:1000, 9172T, CST) and β-actin (1:1000, 4967S, CST).

Techniques: Expressing, Quantitative RT-PCR, Knockdown, Western Blot, Analysis

Journal: Cancer immunology research

Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer

doi: 10.1158/2326-6066.CIR-26-0278

Figure Lengend Snippet: (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing STAT1 and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

Article Snippet: Blots were blocked with 5% non-fat dry milk (BioRad, 1706404) in PBS, then probed with the following antibodies in 5% BSA (Sigma-Aldrich, A7906) solution: MERTK (Cell Signaling Technology (CST), 38102), AXL (CST, 8661, RRID:AB_11217435), p44/42 (CST, 9102, RRID:AB_330744), p-p44/42 (CST, 9101, RRID:AB_331646), iNOS (CST, 13120, RRID:AB_2799268), PD-L1 (R&D Systems, AF1019, RRID:AB_354540), p-STAT1 (CST, 8062, RRID:AB_10949108), Arg1(CST, 93668, RRID:AB_2800207), and SOCS1 (CST, 55313).

Techniques: Inhibition, Extraction, Flow Cytometry, Analysis, Quantitative Proteomics, Expressing, Western Blot, Marker, In Vitro